UPC
Universe Pharmaceuticals Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CN
$4.03
−6.93%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 37.0M | 17.9M | 23.0M | 32.3M | 40.1M |
| Cost of Revenue | 24.7M | 11.6M | 17.0M | 22.0M | 18.3M |
| Gross Profit | 12.4M | 6.3M | 6.1M | 10.3M | 21.9M |
| Operating Expenses | |||||
| R&D Expense | 3.7M | 671.8K | 3.0M | 4.9M | 7.6M |
| SG&A Expense | 18.8M | 8.0M | 10.4M | 9.0M | 21.3M |
| General & Admin Expense | 3.2M | 4.2M | 3.2M | 2.2M | 3.0M |
| Selling & Marketing Expense | 7.3M | 3.8M | 7.3M | 6.8M | 18.3M |
| Other Expenses | 566.8K | 543.0K | 616.3K | (17.5K) | (7.5K) |
| Total Operating Expenses | 23.1M | 9.2M | 14.1M | 13.8M | 28.9M |
| Cost and Expenses | 47.7M | 20.8M | 31.0M | 36.3M | 47.2M |
| Operating Income (EBIT) | (10.7M) | (2.9M) | (8.0M) | (3.5M) | (7.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 499.8K | 232.0K | 278.2K | 156.8K | 162.4K |
| Net Interest Income | (499.8K) | (232.0K) | (278.2K) | (156.8K) | (162.4K) |
| Other Non-Op Income/Expense | 9.8M | (756.1K) | (100.8K) | (413.8K) | (545.3K) |
| Non-Operating Income (excl Interest) | (10.2M) | 524.1K | (177.4K) | 166.0K | (87.5K) |
| EBT (Pre-Tax Income) | (911.2K) | (3.7M) | (8.1M) | (3.9M) | (8.0M) |
| Income Tax Expense | (58.4K) | — | 606.7K | 2.3M | 752.4K |
| Bottom Line | |||||
| Net Income | (852.7K) | (3.7M) | (8.7M) | (6.2M) | (8.7M) |
| Earnings from Cont. Ops | (852.7K) | (3.7M) | (8.7M) | (6.2M) | (8.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (852.7K) | (3.7M) | (8.7M) | (6.2M) | (8.7M) |
| Per Share | |||||
| Basic EPS | ($228.06) | ($1,055.75) | ($1,436.12) | ($1,040.53) | ($1,475.02) |
| Diluted EPS | ($228.06) | ($1,055.75) | ($1,436.12) | ($1,040.53) | ($1,475.02) |
| Revenue Per Share | $65.74 | $5,134.77 | $3,788.79 | $5,454.79 | $6,777.50 |
| Shares | |||||
| Basic Shares Outstanding | 563338 | 3478 | 6077 | 5923 | 5923 |
| Diluted Shares Outstanding | 563338 | 3478 | 6077 | 5923 | 5923 |
| Profitability Metrics | |||||
| EBITDA | 502.7K | (2.9M) | (7.4M) | (3.2M) | (6.4M) |
| D&A | 985.5K | 517.4K | 485.7K | 508.8K | 533.9K |
| EBIT | (482.9K) | (3.4M) | (7.8M) | (3.7M) | (6.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026